Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Exclusive: Suspected North Korean hackers targeted COVID vaccine maker AstraZeneca - sources

11/27/2020 | 06:49am EST
FILE PHOTO: FILE PHOTO: A test tube labelled with the vaccine is seen in front of AstraZeneca logo in this illustration taken

LONDON (Reuters) - Suspected North Korean hackers have tried to break into the systems of British drugmaker AstraZeneca in recent weeks, two people with knowledge of the matter told Reuters, as the company races to deploy its vaccine for the COVID-19 virus.

The hackers posed as recruiters on networking site LinkedIn and WhatsApp to approach AstraZeneca staff with fake job offers, the sources said. They then sent documents purporting to be job descriptions that were laced with malicious code designed to gain access to a victim's computer.

The hacking attempts targeted a "broad set of people" including staff working on COVID-19 research, said one of the sources, but are not thought to have been successful.

The North Korean mission to the United Nations in Geneva did not respond to a request for comment. Pyongyang has previously denied carrying out cyberattacks. It has no direct line of contact for foreign media.

AstraZeneca, which has emerged as one of the top three COVID-19 vaccine developers, declined to comment.

The sources, who spoke on condition of anonymity to discuss non-public information, said the tools and techniques used in the attacks showed they were part of an ongoing hacking campaign that U.S. officials and cybersecurity researchers have attributed to North Korea.

The campaign has previously focused on defence companies and media organisations but pivoted to COVID-related targets in recent weeks, according to three people who have investigated the attacks.

Cyberattacks against health bodies, vaccine scientists and drugmakers have soared during the COVID-19 pandemic as state-backed and criminal hacking groups scramble to obtain the latest research and information about the outbreak.

Western officials say any stolen information could be sold for profit, used to extort the victims, or give foreign governments a valuable strategic advantage as they fight to contain a disease that has killed 1.4 million people worldwide.

Microsoft said this month it had seen two North Korean hacking groups target vaccine developers in multiple countries, including by "sending messages with fabricated job descriptions." Microsoft did not name any of the targeted organisations.

South Korean lawmakers said on Friday that the country's intelligence agency had foiled some of those attempts.

Reuters has previously reported that hackers from Iran, China and Russia have attempted to break into leading drugmakers and even the World Health Organisation this year. Tehran, Beijing and Moscow have all denied the allegations.

Some of the accounts used in the attacks on AstraZeneca were registered to Russian email addresses, one of the sources said, in a possible attempt to mislead investigators.

North Korea has been blamed by U.S. prosecutors for some of the world's most audacious and damaging cyberattacks, including the hack and leak of emails from Sony Pictures in 2014, the 2016 theft of $81 million from the Central Bank of Bangladesh, and unleashing the Wannacry ransomware virus in 2017.

Pyongyang has described the allegations as part of attempts by Washington to smear its image.

(Additional reporting by Stephanie Ulmer-Nebehay in GENEVA; Editing by Philippa Fletcher)

By Jack Stubbs


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.66% 7777 Delayed Quote.6.19%
MICROSOFT CORPORATION 0.44% 225.95 Delayed Quote.1.15%
SONY CORPORATION -1.18% 10480 End-of-day quote.1.90%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) 0.07% 75.172 Delayed Quote.0.19%
All news about ASTRAZENECA PLC
01:09pUK vaccine roll-out speeds up but doctors want quicker second dose
RE
12:50pAstraZeneca's Covid-19 Vaccine Shortfall Threatens EU Plans to Boost Inoculat..
DJ
11:41aPFIZER : UK doctors seek review of 12-week gap between vaccine doses
AQ
11:38aItaly PM says vaccine supply delays are serious contract violations
RE
03:45aASTRAZENECA : UK doctors call for shorter gap between Pfizer vaccine doses
RE
01/22Health Care Down Amid Vaccine-Rollout Concerns -- Health Care Roundup
DJ
01/22THE LATEST : Online vaccine appointments filling up in Kansas
AQ
01/22ALEXION INVESTOR ALERT BY THE FORMER : Kahn Swick & Foti, LLC Investigates Adequ..
BU
01/22Pfizer to supply 40M COVID-19 shots for poor countries
AQ
01/22ASTRAZENECA : to supply 31 mln COVID-19 shots to EU in first quarter, a 60% cut ..
RE
More news
Financials (USD)
Sales 2020 26 404 M - -
Net income 2020 2 955 M - -
Net Debt 2020 13 238 M - -
P/E ratio 2020 42,5x
Yield 2020 2,65%
Capitalization 140 B 139 B -
EV / Sales 2020 5,79x
EV / Sales 2021 4,98x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 126,44 $
Last Close Price 106,39 $
Spread / Highest target 46,7%
Spread / Average Target 18,8%
Spread / Lowest Target -15,2%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC6.19%139 483
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159